Table 3

Age-stratified results: adjusted analyses*

OutcomeBaseline A1C
<6.06.0–6.97.0–7.98.0–8.9≥9
Mortality
 Age-group
  60–6910.92 (0.79–1.07)0.83 (0.70–0.99)0.91 (0.74–1.11)1.17 (0.96–1.43)
  70–7910.83 (0.75–0.92)0.85 (0.75–0.96)0.86 (0.73–1.01)1.11 (0.93–1.32)
  ≥80 10.83 (0.74–0.93)0.83 (0.72–0.95)1.05 (0.86–1.27)1.20 (0.96–1.50)
Any complication
 Age-group
  60–6911.12 (1.00–1.25)1.20 (1.07–1.35)1.44 (1.26–1.64)1.58 (1.38–1.81)
  70–7911.08 (0.98–1.19)1.21 (1.09–1.35)1.35 (1.19–1.53)1.50 (1.30–1.73)
  ≥8011.11 (0.97–1.27)1.18 (1.02–1.38)1.28 (1.03–1.58)1.43 (1.12–1.83)
Any complication or death
 Age-group
  60–6911.04 (0.94–1.14)1.08 (0.98–1.20)1.28 (1.14–1.44)1.43 (1.27–1.60)
  70–7910.98 (0.91–1.06)1.07 (0.98–1.17)1.18 (1.06–1.31)1.36 (1.20–1.53)
  ≥80 10.94 (0.86–1.04)0.96 (0.85–1.07)1.13 (0.96–1.33)1.25 (1.04–1.51)
  • *Models adjusted for sex; race/ethnicity; duration of diabetes; systolic blood pressure; use of insulin, sulfonylurea, or thiazolidinedione; smoking status; glucose-monitoring adherence; GFR (chronic kidney disease stages 1–5); microalbuminuria; and proteinuria.